Company’s 36-month beta value is 1.79.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IPSC is 40.56M, and currently, short sellers hold a 6.78% ratio of that floaft. The average trading volume of IPSC on May 20, 2025 was 595.42K shares.
IPSC) stock’s latest price update
Century Therapeutics Inc (NASDAQ: IPSC) has seen a rise in its stock price by 13.44 in relation to its previous close of 0.55. However, the company has experienced a 19.54% gain in its stock price over the last five trading sessions. zacks.com reported 2025-05-15 that Century Therapeutics, Inc. (IPSC) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.45 per share a year ago.
IPSC’s Market Performance
IPSC’s stock has risen by 19.54% in the past week, with a monthly rise of 16.44% and a quarterly drop of -17.08%. The volatility ratio for the week is 8.53% while the volatility levels for the last 30 days are 7.25% for Century Therapeutics Inc The simple moving average for the last 20 days is 17.63% for IPSC stock, with a simple moving average of -42.40% for the last 200 days.
Analysts’ Opinion of IPSC
Many brokerage firms have already submitted their reports for IPSC stocks, with Rodman & Renshaw repeating the rating for IPSC by listing it as a “Buy.” The predicted price for IPSC in the upcoming period, according to Rodman & Renshaw is $6 based on the research report published on August 08, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see IPSC reach a price target of $5, previously predicting the price at $28. The rating they have provided for IPSC stocks is “Neutral” according to the report published on August 28th, 2023.
Chardan Capital Markets gave a rating of “Buy” to IPSC, setting the target price at $19 in the report published on December 27th of the previous year.
IPSC Trading at 19.86% from the 50-Day Moving Average
After a stumble in the market that brought IPSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.88% of loss for the given period.
Volatility was left at 7.25%, however, over the last 30 days, the volatility rate increased by 8.53%, as shares surge +15.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.27% upper at present.
During the last 5 trading sessions, IPSC rose by +18.33%, which changed the moving average for the period of 200-days by -70.22% in comparison to the 20-day moving average, which settled at $0.5342. In addition, Century Therapeutics Inc saw -37.74% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IPSC starting from Pfeiffenberger Brent, who proposed sale 29,552 shares at the price of $0.55 back on May 16 ’25. After this action, Pfeiffenberger Brent now owns shares of Century Therapeutics Inc, valued at $16,138 using the latest closing price.
Farid Adrienne, the Chief Operations Officer of Century Therapeutics Inc, sale 1,024 shares at $0.55 during a trade that took place back on May 05 ’25, which means that Farid Adrienne is holding 250,693 shares at $563 based on the most recent closing price.
Stock Fundamentals for IPSC
Current profitability levels for the company are sitting at:
- -0.29 for the present operating margin
- -0.04 for the gross margin
The net margin for Century Therapeutics Inc stands at -0.19. The total capital return value is set at -0.11. Equity return is now at value -10.49, with -6.61 for asset returns.
Based on Century Therapeutics Inc (IPSC), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -2.4.
Currently, EBITDA for the company is -111.47 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.70.
Conclusion
In a nutshell, Century Therapeutics Inc (IPSC) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
